Making use of this differential NCAM1 expression, we provided proof of concept for engineered T cell functional selection by showing that sorted NCAM1+CD8+ TEGs have a greater capacity to kill various BC PDOs compared with NCAM1−CD8+ TEGs (Fig. 4g and Extended Data Fig. 4i). This evidence concerns the gene NCAM1 and breast cancer.